About Stempeutics
Stempeutics is a Healthcare company based in Bengaluru (India) founded in 2006. Stem-cell-based products are developed for osteoarthritis and Buergers disease. Stempeutics has raised $47.3 million across 13 funding rounds from investors including Manipal Group, Cipla and Max Medisupport. The company has 27 employees. Stempeutics was last valued at $53.47 million in April 2021. Its Indian entity Stempeutics Research Private Limited reported revenue of ₹17.88 Cr. Stempeutics offers products and services including Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Cell Therapy and Stem Cells.
Company details
Stempeutics, a joint venture between Cipla and Manipal develops stem-cell based products. Its lead product Stempeucel is an off-the-shelf product comprised of adult allogeneic mesenchymal stem cells derived from multiple bone marrow donors. In 2016 DCGI (Indian FDA) granted its limited approval for the treatment of CLI patients due to Buergers disease. It is also in clinical trials for critical limb ischemia, osteoarthritis, liver cirrhosis, acute myocardial infraction and ICM (Ischemic Cardiomyopathy) in India and Malaysia. Besides, it also developed Stempeutron, a point-of-care device for automated isolation of autologous stromal vascular fraction (SVF) cells from adipose tissue. It also has a line of OTC stem cell based cosmetic products called Stempeucare.
- Headquarters Bengaluru, India
- Employees 27
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website stempeutics.com
- Social LinkedIn X
- Legal Name Stempeutics Research Private Limited
- Date of Incorporation 16 Jan, 2006
- Jurisdiction Bengaluru, Karnataka, India
- Annual Revenue₹17.88 Cr
FY 2025 · +96% YoY
- Net Loss-₹12.84 Cr
FY 2025 · -72% margin
- EBITDA-₹12.48 Cr
FY 2025 · -70% margin
- Total Equity Funding$47.3M (USD)
in 13 rounds
- Latest Funding Round$1.73M (USD), Series B
Apr 2021
- InvestorsManipal Group
& 5 more
- Employee Count27
Associated legal entities of Stempeutics
Stempeutics operates through Stempeutics Research Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Stempeutics Research Private Limited CIN U73100KA2006PTC038256 | Active | 16 Jan 2006 | Bengaluru, Karnataka | ₹17.9 Cr | 27 | 6 | View details |
Products & Services of Stempeutics
Stempeutics offers a comprehensive portfolio of products and services, including Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®.
Stem cell therapy for treating critical limb ischemia and osteoarthritis.
Stem cell-based product for firming and moisturizing skin.
Bio-active serum to promote hair growth and reduce hair fall.
Concentrate for reducing under-eye dark circles and soothing skin.
Funding Insights of Stempeutics
Stempeutics has successfully raised a total of $47.3M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $1.73 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $47.3M
- Total Rounds 13
- Last Round Series B — $1.73M
- First Round $1.54M
(Mar 2007)
- Investors Count 6
Latest 10 of 13 funding rounds of Stempeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $1.73M | Series B | $53.47M | Max Medisupport | – |
| Jul 2020 | $663,678 | Series B | $51.69M | Max Medisupport | – |
| May 2019 | $5.56M | Series B | $••••• | Max Medisupport | |
| Jul 2016 | $2.26M | Series B | $••••• | MNI Ventures | |
| Mar 2015 | $6.84M | Series A | $••••• | MNI Ventures | |
| Jun 2014 | $4.06M | Series A | $••••• | Manipal Group | |
| Aug 2012 | $7.93M | Series A | $••••• | Meditab Specialities | |
| Oct 2011 | $1.19M | Series A | $••••• | Meditab Specialities | – |
| Dec 2010 | $452,626 | Series A | $••••• | Meditab Specialities | – |
| Apr 2010 | $12.45M | Series A | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Apr 2021 | $53.47M | •••••••• |
| Jul 2020 | $51.69M | •••••••• |
| May 2019 | $••••• | •••••••• |
| Jul 2016 | $••••• | •••••••• |
| Mar 2015 | $••••• | •••••••• |
| Jun 2014 | $••••• | •••••••• |
| Aug 2012 | $••••• | •••••••• |
| Oct 2011 | $••••• | •••••••• |
Full valuation and stage history of Stempeutics
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $53.47M (Apr 2021). 6 investors in total: 6 institutional.
Investors in Stempeutics
Stempeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Manipal Group, Cipla and Max Medisupport.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on multiple sectors | mniventures.tcc.mode | Port Louis, Mauritius | ||
Provides comprehensive business management software solutions for hospitals. | 2010 | maxmedisupport.com | Bengaluru, India | |
Education, healthcare, insurance, and research services are provided globally. | 1993 | manipalgroup.com | Bengaluru, India | |
| meditabspecialities.tcc.mode | ||||
APIs, generic drugs, and formulation services are manufactured. | 1935 | cipla.com | Mumbai, India | |
| melodymedicines.tcc.mode |
Investor details for Stempeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Stempeutics Research Private Limited (Stempeutics)
Stempeutics Research Private Limited is the primary company behind Stempeutics. The board of Stempeutics Research Private Limited currently have 5 directors; the longest-serving is Manohar Balu Narasimhan, appointed in 2009. 18 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Manohar Balu Narasimhan DIN 00322394 | Managing Director | 26 Aug 2009 | 17 yrs 2 mo | Stempeutics Research Private Limited |
| Hebri Sudarshan Ballal DIN 01195055 | Director | 19 Jan 2012 | 14 yrs 9 mo | Stempeutics Research Private Limited |
| Jaideep Ashok Gogtay DIN 03137772 | Nominee Director | 28 Mar 2019 | 7 yrs 7 mo | Stempeutics Research Private Limited |
| Anurag Bagaria DIN 00111917 | Director | 27 Jun 2019 | 7 yrs 4 mo | Stempeutics Research Private Limited |
| Umang Vohra DIN 02296740 | Director | 24 Feb 2023 | 3 yrs 8 mo | Stempeutics Research Private Limited |
Financials of Stempeutics
Figures of Stempeutics Research Private Limited, the primary company behind Stempeutics, for FY 2025. Revenue was ₹17.88 Cr (+96% year on year). Net loss was -₹12.84 Cr (-72% margin). EBITDA was -₹12.48 Cr (-70% margin). Revenue has grown at a compounded annual rate of +79% over three years and +14% over five years.
- ₹17.88 CrRevenue · FY 2025 · +96% YoY
- -₹12.84 CrNet loss · -72% margin
- -₹12.48 CrEBITDA · -70% margin
- ₹63.62 CrPaid-up capital
- 27Employees (provident fund records)
- +79%Revenue CAGR, 3 years
- +14%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Stempeutics Research Private Limited are on its company page.
Detailed financial statements for Stempeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Stempeutics
4 dated milestones of Stempeutics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Stempeutics is founded.
- Funding First funding round of $1.5M.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series B, of $1.7M.
Web traffic of Stempeutics
The website of Stempeutics (stempeutics.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▲ 20.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stempeutics
Complete news archive for Stempeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stempeutics
Stempeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Stempeutics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Stempeutics is a funded company, having raised a total of $47.3M across 13 funding rounds to date. The company's 1st funding round was a Series A of $12.45M, raised on Mar 2007.
Stempeutics has 27 employees.
The primary company behind Stempeutics, Stempeutics Research Private Limited, reported revenue of ₹17.88 Cr for FY 2025, up 96% year on year.
Stempeutics, a joint venture between Cipla and Manipal develops stem-cell based products. Its lead product Stempeucel is an off-the-shelf product comprised of adult allogeneic mesenchymal stem cells derived from multiple bone marrow donors. In 2016 DCGI (Indian FDA) granted its limited approval for the treatment of CLI patients due to Buergers disease. It is also in clinical trials for critical limb ischemia, osteoarthritis, liver cirrhosis, acute myocardial infraction and ICM (Ischemic Cardiomyopathy) in India and Malaysia. Besides, it also developed Stempeutron, a point-of-care device for automated isolation of autologous stromal vascular fraction (SVF) cells from adipose tissue. It also has a line of OTC stem cell based cosmetic products called Stempeucare.
Stempeutics offers Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®.
Stempeutics has 6 investors. Key investors include Manipal Group, Cipla, Max Medisupport, MNI Ventures, and Meditab Specialities.
The valuation of Stempeutics is $53.47M as of Apr 2021.
Stempeutics operates through Stempeutics Research Private Limited.
The legal entities of Stempeutics currently have 6 directors, including Jaideep Ashok Gogtay, Hebri Sudarshan Ballal, Umang Vohra and others.